Peter Abdelmessieh, DO
Medical Oncology · Robbinsville, NJNPI 1073803896
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,350 of the $10,944 with a category attached, or 67.2%. Amgen accounts for 61.5% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2024 at $4,600 and has fallen 50.6% since, to $2,272 in 2025.
Across 86 payments — averaging $127.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- CTI Biopharma Corp.$2K
- GSK$430
- AstraZeneca$388
- E.r. Squibb & Sons, L.L.C.$256
- Johnson & Johnson$196
- plus $1K from 20 others
Across 2 payments — averaging $12,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$25K
What the payments were for
- Consulting fees$2,14820%
- Speaking & faculty fees$7,35067%
- Food & beverage$1,37413%
- Education$721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 10 | $6,736 |
| CTI Biopharma Corp. | 1 | $1,725 |
| GSK | 1 | $430 |
| AstraZeneca(2 entities) | 8 | $388 |
| E.r. Squibb & Sons, L.L.C. | 5 | $256 |
| Johnson & Johnson | 8 | $196 |
| Sanofi | 4 | $174 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| Novartis | 6 | $106 |
| Genentech USA, Inc. | 5 | $104 |
| Merck | 5 | $89 |
| Bristol Myers Squibb | 3 | $80 |
| Gilead(2 entities) | 4 | $75 |
| AbbVie | 5 | $74 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $60 |
| Pfizer | 3 | $50 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| Incyte Corporation | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Shire North American Group Inc | 1 | $18 |
| Partner Therapeutics, Inc. | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,944 in reported general payments places this provider in the 70th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 24 | $410,881 |
| VonjoPacritinib Citrate | 13 | $316,478 |
| ImbruvicaIbrutinib | 11 | $179,852 |
| InqoviDecitabine/Cedazuridine | 21 | $171,987 |
| Imatinib Mesylate | 14 | $34,005 |
| Acyclovir | 35 | $417 |
| Fluconazole | 11 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $23 | $410,88124 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $60 | $179,85211 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $31 | $41735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Robbinsville
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
- David SiegelHackensack$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.